Therapy related myeloid neoplasms (t-MN) including therapy related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML) are associated with aggressive disease biologies and poor outcomes. In this large (n 5 497) and informative (inclusive of molecular and cytogenetic information) chronic myelomonocytic leukemia (CMML) patient cohort, we demonstrate key biological insights and an independent prognostic impact for t-CMML. T-CMML was diagnosed in 9% of patients and occurred approximately 7 years after exposure to prior chemotherapy and/or radiation therapy. In comparison to de novo CMML, t-CMML patients had higher LDH levels, higher frequency of karyotypic abnormalities and had higher risk cytogenetic stratification. There were no differences in the distribution of gene mutations and unlike t-MDS/AML, balanced chromosomal translocations, abnormalities of chromosome 11q23 (1%) and Tp53 mutations (<2%) were uncommon. Molecularly integrated CMML prognostic models were not effective in risk stratifying t-CMML patients and responses to hypomethylating agents were dismal with no complete responses. Median overall (OS) and leukemia free survival (LFS) was shorter for t-CMML in comparison to d-CMML (Median OS 10.9 vs 26 months and median LFS 50 vs 127 months) and t-CMML independently and adversely impacted OS (P 5 .0001 HR 2.1 95% CI 1.4-3.0). This prognostic impact was retained in the context of the Mayo Molecular Model (P 5 .001, HR 2.4, 95% CI 1.5-3.7) and the GFM prognostic model (P < .0001, HR 2.15, 95% CI 1.5-3.7). In summary, we highlight the unique genetics and independent prognostic impact of t-CMML, warranting its inclusion as a separate entity in the classification schema for both CMML and t-MN. 
| I N TR ODU C TI ON
The 2016 iteration of the World Health Organization (WHO) classification of myeloid neoplasms has retained therapy-related myeloid neoplasms (t-MN) as a distinct category for patients who develop myeloid neoplasms following exposure to cytotoxic therapy or ionizing radiation for prior neoplastic or non-neoplastic disorders. 1 The t-MN are further sub-classified as therapy-related MDS (myelodysplastic syndrome) or AML (acute myeloid leukemia), with the important caveat that the associated cytogenetic abnormality, often determining prognosis, should be mentioned in the final diagnosis. 1 Depending on the type of exposure, t-MN can broadly be divided into (i) t-MDS/AML occurring after exposure to alkylating agents and/or radiation and (ii) t-AML related to exposure to DNA topoisomerase-II inhibitors. 2 T-MDS/AML occurring after exposure to alkylating agents usually has a latent period of [5] [6] [7] [8] [9] [10] years, is commonly associated with unbalanced losses of chromosomes 5 and 7, and often presents with MDS followed by blast transformation; while t-AML related to DNA topoisomerase-II inhibitors have a shorter latent period (1-5 years) and are usually associated with balanced chromosomal translocations or abnormalities of chromosome 11q23 (KMT2A/MLL1 gene).
inherent risk for blast transformation. [3] [4] [5] Patients with CMML have a unique molecular landscape, with gene mutations involving epigenetic regulator genes (TET2 60%), spliceosome components (SRSF2 50%), chromatin regulation (ASXL1 40%) and cell signaling (oncogenic RAS pathway 30%) being common; whereas clonal cytogenetic changes are seen in approximately 30% of patients. [3] [4] [5] [6] [7] [8] Therapy related CMML (t-CMML) has been described, with an approximate frequency of 11% of all CMML cases, with a higher predilection for high risk clonal cytogenetic abnormalities and with a shorter median over-all (OS) and leukemia free survival (LFS), in comparison to de novo CMML (d-CMML). 9, 10 We carried out this study in a larger, more informative data set of WHO defined CMML patients to (i) describe the clinical, laboratory, cytogenetic and molecular correlates of t-CMML, (ii) assess the prognostic impact of t-CMML in comparison to d-CMML, and (iii) to describe survival outcomes.
| M E TH ODS
After approval by the Mayo Clinic institutional review board, Mayo
Clinic databases and cell banks were queried to identify patients with CMML. All patients had bone marrow (BM) biopsies and cytogenetic studies performed at diagnosis. TET2, DNMT3A, IDH1, IDH2, ASXL1, EZH2, SUZ12, SRSF2,   SF3B1, ZRSR2, U2AF1, PTPN11, Tp53, SH2B3, RUNX1, CBL, NRAS,   KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF, BCOR, and SETBP1, by previously described methods. 4 The flow cells were sequenced as 101 X 2 paired end reads on an Cytogenetics; n (% of abnormal karyotype) .001 58%, ASXL1 51%, SRSF2 48%, NRAS 15%, SETBP1 14%, CBL 13%, JAK2V617F 8%, U2AF1 7%, DNMT3A and IDH2 6% each, KRAS 5%, PTPN11, ZRSR2, Tp53 and EZH2 3% each, IDH1, RUNX1 and CSF3R 2% each ( Table 1 ). There were no statistically significant differences in mutational frequencies between t-CMML and d-CMML. morphological subtypes, abnormal karyotype and the aforementioned gene mutations; older age (P 5 .02), male sex (P 5 .007), low HB (P < .0001), high WBC (P < .0001), high AMC (P < .0001), high ALC (P 5 .012), presence of IMC (P < .0001), PB blast % (P < .0001), BM blast % (P 5 .0004), high LDH levels (P 5 .0032), t-CMML (P < .0001), proliferative CMML (P 5 .001), abnormal karyotype (P < .0001), absence of TET2 (P 5 .02) mutations and the presence of ASXL1 older age (P 5 .0008), low HB (P 5 .01), high ALC (P 5 .009), PB blast % (P < .0001), BM blast % (P < .0001), t-CMML (P 5 .03), abnormal karyotype (P 5 .0003), presence of DNMT3A (P 5 .0009), IDH2 (P 5 .04) and
Tp53 (P 5 .0001) mutations, adversely impacted LFS. In a multivariable analysis that included the aforementioned significant variables, only older age (P 5 .01, HR 1.1 95% CI 1.1-2.1), PB blast % (P < .0001, HR Table) .
Eleven (24%) of 45 t-CMML patients were treated with hypomethylating agents (Aazacitidine-7, decitabine 4), for a median of 4 cycles (range, 1-9). There were no complete responses noted with most patients demonstrating refractory disease (60%) or eventual disease progression to acute myeloid leukemia (30%).
| D ISC USSION
Therapy related myeloid neoplasms occur after prior exposure to CT and/or RT for primary underlying malignancies or nonmalignant immune conditions, and are associated with poor outcomes. 1,2 Well defined categories of t-MN include t-MDS and t-AML, with smaller series identifying potential therapy related CMML patients. 10, 17 With the help of this large (n 5 497) and informative data set (inclusive of cytogenetic and molecular data) of WHO defined CMML patients, we clearly establish the unique biological constitution and prognostic relevance of t-CMML.
T-CMML constitutes approximately 9-11% of all CMML cases and tends to occur 5-7 years after exposure to CT and/or RT. 9, 10 In comparison to d-CMML, t-CMML patients have a higher frequency of cytogenetic abnormalities, have higher risk karyotypes and have higher risk stratification by CMML specific cytogenetic models; findings validated by the current study. We also demonstrate higher baseline LDH levels in t-CMML patients, with LDH levels having been shown to be a negative prognosticator in the Dusseldorf CMML model. 17 In our series, most CT related cases occurred after exposure to alkylating agents, while most RT In a prior study, investigators assessed the prevalence and clinical correlates of t-CMML amongst 358 CMML patients. 10 Thirty-nine (11%) patients met criteria for t-CMML, with the median age being 69 years. The two groups (t-CMML vs d-CMML) were comparable with regards to most clinical and laboratory variables with the exception of higher risk cytogenetic abnormalities and higher risk cytogenetic stratification in the t-CMML group. The most common primary underlying malignancies were lymphoproliferative disorders (37%), followed by prostate (31%) and breast cancer (13%). Similar to our study, the median OS and LFS for t-CMML (13 months and 9 months) were significantly shorter in comparison to d-CMML (22 months and 16 months). 10 There were also no differences in survival between t-CMML that arose after exposure to CT, RT or combined modality therapy. In a survival analysis the adverse prognostic effect of t-CMML was thought to be fully accounted for by cytogenetics, however, in our study, which included a larger number of patients, the adverse prognostic impact of t-CMML was independent of cytogenetic abnormalities and cytogenetic risk stratification.
Our study was the first to assess the distribution and impact of gene mutations in t-CMML. CMML patients have approximately 10-15 gene mutations per kilobase of coding DNA regions. 18 Common mutations include TET2 60%, SRSF2 50%, ASXL1 40%, KRAS/NRAS/ CBL 40% and SETBP1 15%, with mutations involving tumor suppressor genes such as Tp53 and PHF6 being uncommon (<2%). 3, 5, 7, 19 In a prior study we demonstrated that in CMML, ASXL1 (P 5 .04) and SF3B1 (P 5 .03) mutations cluster with an abnormal karyotype, whereas SRSF2 (P 5 .02) mutations occur more commonly in the setting of a normal karyotype. 8 In the current study, although there were more cytogenetic abnormalities in t-CMML, there were no differences in the distribution of gene mutations between the two groups. While somatic Tp53 mutations are seen in approximately 30% of patients with t-AML/t-MDS, are associated with complex/monosomal karyotypes and are associated with a negative prognostic impact, our study once again confirms that these mutations are uncommon in CMML (<2%) and are equally distributed between t-CMML and d-CMML. 20, 21 While Tp53 mutations did not impact OS, they independently and negatively impacted LFS.
CMML prognostic models have been developed from patient cohorts that have largely included patients with d-CMML. 3, 12, 14, 15 While in MDS, conventional prognostic models such as the international prognostic scoring system (IPSS) and the revised-IPSS are ineffective for risk stratification of t-MDS patients, the ability of CMML models to risk stratify t-CMML patients remains to be determined. [22] [23] [24] In our study, only the Mayo Model was effective in risk stratification of t-CMML patients with regards to OS (Figure 3 ), while ASXL1 integrated models, including the MMM, GFM model and the CPSS-Mol model were less effective; although, this analysis was hampered by a smaller number of molecularly annotated patients.
Hypomethylating agents (HMA) such as 5-azacitidine and decitabine have been used to treat patients with CMML, with overall response rates of 40-50% and complete response rates of <20%.
5,25
Elaborate genomic and epigenetic sequencing data has shown that these drugs restore normal hematopoiesis in responders in an epigenetic manner, without affecting the mutational allele burdens, or significantly impacting the risk of disease progression. 18 In our study, 11 patients with t-CMML were treated with HMA, with 0% complete responses and with 30% progressing to AML on therapy, indicative of dismal responses of t-CMML patients to these agents.
We hereby demonstrate that t-CMML is a unique CMML sub-type that occurs after exposure to CT/RT for primary underlying malignancies or immune mediated conditions. Patients with t-CMML have a higher frequency of cytogenetic abnormalities with higher risk karyotypic stratification and have a shorted median OS and LFS in comparison to d-CMML. While the distribution of gene mutations is similar, contemporary molecularly integrated CMML prognostic models are less useful in risk stratifying these patients. Responses to HMA are dismal, indicating the urgent and unmet need to develop new therapies for these patients. We hence conclude that given the unique biological make up and independent prognostic relevance, t-CMML should be considered as a separate CMML subtype in the classification schema for both CMML and t-MN.
